Characteristics of patients with NDMM
| . | All . | Low . | High . |
|---|---|---|---|
| Patient characteristics | |||
| Median age | 65 | 62 | 65 |
| Sex, no. (%) | |||
| Male | 17 (65.4) | 8 (61.5) | 9 (69.2) |
| Female | 9 (34.6) | 5 (38.5) | 4 (30.8) |
| Cytogenetic risk (no. of patients) | |||
| Standard | 14 | 7 | 7 |
| High | 7 | 2 | 5 |
| Ultrahigh | 3 | 2 | 1 |
| Not assessed | 2 | 2 | 0 |
| Medianfollow-uptime (mo) | 51 | 59 | 45 |
| HAPLN1 concentration (μg/mL) | |||
| Mean ± SD | 0.71 ± 0.80 | 0.36 ± 0.05 | 1.06 ± 1.03 |
| Median PFS (mo) | 42 | 57 | 28 |
| HR (95% CI) | 3.027 (1.135-8.072) | ||
| P value (log-rank) | .0164 | ||
| . | All . | Low . | High . |
|---|---|---|---|
| Patient characteristics | |||
| Median age | 65 | 62 | 65 |
| Sex, no. (%) | |||
| Male | 17 (65.4) | 8 (61.5) | 9 (69.2) |
| Female | 9 (34.6) | 5 (38.5) | 4 (30.8) |
| Cytogenetic risk (no. of patients) | |||
| Standard | 14 | 7 | 7 |
| High | 7 | 2 | 5 |
| Ultrahigh | 3 | 2 | 1 |
| Not assessed | 2 | 2 | 0 |
| Medianfollow-uptime (mo) | 51 | 59 | 45 |
| HAPLN1 concentration (μg/mL) | |||
| Mean ± SD | 0.71 ± 0.80 | 0.36 ± 0.05 | 1.06 ± 1.03 |
| Median PFS (mo) | 42 | 57 | 28 |
| HR (95% CI) | 3.027 (1.135-8.072) | ||
| P value (log-rank) | .0164 | ||
CI, confidence interval; SD, standard deviation.